Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Review Article

Lipid lowering: another method of reducing blood pressure?

Journal of Human Hypertension volume 16, pages 753–760 (2002)Cite this article

Abstract

Modern management of cardiovascular risk depends on assessment of cardiovascular risk factors. Hypertension and hyperlipidaemia are synergistic risk factors for cardiovascular events. Both show a degree of cross-correlation through sharing mechanisms of pathogenesis including insulin resistance and endothelial dysfunction. This article reviews the common pathways leading to dyslipidaemia and hypertension and the effects diet and lipid-lowering drug therapies have had on correcting blood pressure in patients with essential hypertension. Both statins and fibrates have shown a capability to lower blood pressure by up to 8/5 and 15/10 mmHg respectively, in some small-scale clinical trials and have effects on arterial wall structure and hence pulse wave velocity. This blood pressure action may account for some of the clinical effects of lipid-lowering drugs on cardiovascular risk. Thus, lipid lowering may provide an additional method of correcting hypertension in some high-risk patients. However, data from large-scale intervention trials are either absent or ambiguous. Definitive large-scale trials to investigate the antihypertensive effects of lipid-lowering drugs are required, although end point studies examining the interaction of lipid-lowering and antihypertensive drugs to determine optimum combinations are already under way.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bonaa KH, Thelle DS . Association of blood pressure and serum lipids in a population: the Tromso study Circulation 1991 83: 1305–1314

    Article  CAS  PubMed  Google Scholar 

  2. Ostrander LD, Lamphiear DE . Coronary risk factors in the community: findings in Tecumseh, Michigan Circulation 1976 53: 152–156

    Article  PubMed  Google Scholar 

  3. Criqui MH et al. Frequency and clustering of non-lipid cardiovascular risk factors in dyslipoproteinemia: the Lipids Research Clinics Program Prevalence Study Circulation 1986 73: I-40–I-50

    CAS  Google Scholar 

  4. Criqui MH et al. Clustering of cardiovascular disease risk factors Prevent Med 1980 9: 523–526

    Article  Google Scholar 

  5. Kannel WB, Wilson PW, Zhang TJ . The epidemiology of impaired glucose tolerance and hypertension Am Heart J 1991 121: 1268–1273

    Article  CAS  PubMed  Google Scholar 

  6. Hopkins PN et al. Hypertension, dyslipidaemia and insulin resistance: links in a chain or spokes on a wheel? Curr Opin Lipidol 1996 7: 241–253

    Article  CAS  PubMed  Google Scholar 

  7. Goode GK, Miller JP, Heagerty AM . Hyperlipidaemia, hypertension, and coronary heart disease Lancet 1995 345: 362–364

    Article  CAS  PubMed  Google Scholar 

  8. Castelli WP, Anderson A . A population at risk; prevalence of high cholesterol levels in hypertensive patients in the Framingham Study Am J Med 1986 80: 23–32

    Article  CAS  PubMed  Google Scholar 

  9. Law MR, Wald NJ, Thompson SG . By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994 308: 367–372

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. de Lorgeril M et al. Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infraction: final report of the Lyon Diet Heart Study Circulation 1999 99: 733–736

    Article  Google Scholar 

  11. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 Polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999 354: 447–455

  12. Nordoy A, Marchioli R, Arnesen H, Videbaek J . n-3 Polyunsaturated fatty acids and cardiovascular diseases Lipids 2001 36: (Suppl) S127–S129

    Article  CAS  PubMed  Google Scholar 

  13. Sacks FM et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group N Engl J Med 2001 344: 3–10

    Article  CAS  PubMed  Google Scholar 

  14. Hardman TC, Lant AF . Controversies surrounding erythrocyte sodium–lithium countertransport J Hypertens 1996 14: 695–703

    Article  CAS  PubMed  Google Scholar 

  15. Hardman TC, Dubrey SW, Soni S, Lant AF . Relation of sodium–lithium countertransport activity to markers of cardiovascular risk in normotensive subjects J Hum Hypertens 1995 9: 589–596

    CAS  PubMed  Google Scholar 

  16. Cirillo M et al. Prospective analysis of traits related to 6-year change in sodium–lithium countertransport. Gubbio Population Study Research Group Hypertension 1999 33: 887–893

    Article  PubMed  Google Scholar 

  17. Rebbeck TR, Turner ST, Michels VV, Moll PP . Genetic and environmental explanations for the distribution of sodium—lithium countertransport in pedigrees from Rochester, MN Am J Hum Genet 1991 48: 1092–1104

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Williams RR et al. Sodium–lithium countertransport in erythrocytes of hypertension prone families in Utah Am J Epidemiol 1983 118: 338–344

    Article  CAS  PubMed  Google Scholar 

  19. Hunt SC et al. A prospective study of sodium–lithium countertransport and hypertension in Utah Hypertension 1991 17: 1–7

    Article  CAS  PubMed  Google Scholar 

  20. Wierzbicki AS et al. Relation between sodium–lithium countertransport and hypertriglyceridemia in type V hyperlipidemia Am J Hypertens 2001 14: 32–37

    Article  CAS  PubMed  Google Scholar 

  21. Allayee H et al. Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p Hypertension 2001 38: 773–778

    Article  CAS  PubMed  Google Scholar 

  22. Kammerer CM et al. Sodium–lithium countertransport activity is linked to chromosome 5 in baboons Hypertension 2001 37: 398–402

    Article  CAS  PubMed  Google Scholar 

  23. Bianchi G, Cusi D . Association and linkage analysis of alpha-adducin polymorphism: is the glass half full or half empty? Am J Hypertens 2000 13: 739–743

    Article  CAS  PubMed  Google Scholar 

  24. Pravenec M et al. Genetic analysis of cardiovascular risk factor clustering in spontaneous hypertension Folia Biol (Krakow) 2000 46: 233–240

    CAS  Google Scholar 

  25. Celermajer DS et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis Lancet 1992 340: 1111–1115

    Article  CAS  PubMed  Google Scholar 

  26. Celermajer DS . Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 1997 30: 325–333

    Article  CAS  PubMed  Google Scholar 

  27. Chowienczyk PJ et al. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity J Am Coll Cardiol 1997 29: 964–968

    Article  CAS  PubMed  Google Scholar 

  28. Simons LA, Sullivan D, Simons J, Celermajer DS . Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe hypercholesterolaemia Atherosclerosis 1998 132: 197–203

    Article  Google Scholar 

  29. Stroes ESG, Koomans HA, de Bruin TWA, Rabelink TJ . Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication Lancet 1995 346: 467–471

    Article  CAS  PubMed  Google Scholar 

  30. Evans M et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus Circulation 2000 101: 1773–1779

    Article  CAS  PubMed  Google Scholar 

  31. Wassmann S et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species Hypertension 2001 37: 1450–1457

    Article  CAS  PubMed  Google Scholar 

  32. Schiffrin EL . A critical review of the role of endothelial factors in the pathogenesis of hypertension J Cardiovasc Pharmacol 2001 38: (Suppl 2) S3–S6

    Article  CAS  PubMed  Google Scholar 

  33. Cockroft JR, Chowienczyk PJ, Ritter JM . Hyperlipidaemia, hypertension and coronary heart disease Lancet 1995 345: 862–863

    Article  Google Scholar 

  34. Pedrinelli R et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men Hypertension 2000 35: 48–54

    Article  CAS  PubMed  Google Scholar 

  35. Deighan CJ et al. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease J Am Soc Nephrol 2001 12: 341–348

    CAS  PubMed  Google Scholar 

  36. Nakamura T et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia Am J Nephrol 2001 21: 449–454

    Article  CAS  PubMed  Google Scholar 

  37. Diercks GF et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]) Am J Cardiol 2000 86: 635–638

    Article  CAS  PubMed  Google Scholar 

  38. Sundstrom J et al. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later Circulation 2001 103: 836–841

    Article  CAS  PubMed  Google Scholar 

  39. Kannel WB . Influence of multiple risk factors on the hazard of hypertension J Cardiovasc Pharmacol 1990 16: (Suppl 5) S53–S57

    Article  PubMed  Google Scholar 

  40. Schillaci G et al. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension J Hypertens 2001 19: 2265–2270

    Article  CAS  PubMed  Google Scholar 

  41. Su S et al. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension Am J Cardiol 2000 86: 514–518

    Article  CAS  PubMed  Google Scholar 

  42. Nickenig G et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men Circulation 1999 100: 2131–2134

    Article  CAS  PubMed  Google Scholar 

  43. Franklin SS et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study Circulation 2001 103: 1245–1249

    Article  CAS  PubMed  Google Scholar 

  44. O'Rourke MF . Wave travel and reflection in the arterial system J Hypertens 1999 17: (Suppl 5) S45–S47

    CAS  Google Scholar 

  45. Wilkinson IB, Cockcroft JR, Webb DJ . Pulse wave analysis and arterial stiffness J Cardiovasc Pharmacol 1998 32: (Suppl 3) S33–S37

    CAS  PubMed  Google Scholar 

  46. O'Rourke MF, Pauca A, Jiang XJ . Pulse wave analysis Br J Clin Pharmacol 2001 51: 507–522

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Meaume S et al. Aortic pulse wave velocity as a marker of cardiovascular disease in subjects over 70 years old J Hypertens 2001 19: 871–877

    Article  CAS  PubMed  Google Scholar 

  48. Blacher J et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients Hypertension 1999 33: 1111–1117

    CAS  PubMed  Google Scholar 

  49. Asmar R et al. Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations Am J Hypertens 2001 14: 91–97

    Article  CAS  PubMed  Google Scholar 

  50. Ferrier KE et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension J Am Coll Cardiol 2002 39: 1020–1025

    Article  CAS  PubMed  Google Scholar 

  51. Arntzenius AC et al. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial N Engl J Med 1985 312: 805–811

    Article  CAS  PubMed  Google Scholar 

  52. Buchwald H et al. Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group JAMA 1992 268: 1429–1433

    Article  CAS  PubMed  Google Scholar 

  53. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease JAMA 1984 251: 351–364

  54. Duffield RG, Miller NE, Jamieson CW, Lewis B . A controlled trial of plasma lipid reduction in peripheral atherosclerosis—an interim report Br J Surg 1982 69: (Suppl) S3–S5

    Article  PubMed  Google Scholar 

  55. Committee of Principal Investigators. A co-operative trial of primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978 40: 1069–1118

  56. Idzior-Walus B et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X Eur J Clin Invest 2000 30: 871–878

    Article  CAS  PubMed  Google Scholar 

  57. Morgan T et al. Simvastatin in the treatment of hypercholesterolemia in patients with essential hypertension J Hypertens 1980 8: (Suppl 1) 525–530

    Google Scholar 

  58. Bradford RH et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia Arch Intern Med 1991 151: 43–49

    Article  CAS  PubMed  Google Scholar 

  59. Sung BH, Izzo Jr JL, Wilson MF . Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol Am J Hypertens 1997 10: 592–599

    Article  CAS  PubMed  Google Scholar 

  60. Jarai Z et al. Effect of fluvastatin on serum lipid levels in essential hypertension.] Orv Hetil 1996 137: 1857–1859

    CAS  PubMed  Google Scholar 

  61. Abetel G, Poget PN, Bonnabry JP . Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study] Schweiz Med Wochenschr 1998 128: 272–277

    CAS  PubMed  Google Scholar 

  62. Li N et al. Pravastatin affects blood pressure and vascular reactivity Heart Vessels 1996 11: 64–68

    Article  CAS  PubMed  Google Scholar 

  63. Murumatsu J, Kobayashi A, Hasegawa N, Yokouchi S . Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin Atherosclerosis 1997 130: 179–182

    Article  Google Scholar 

  64. Glorioso N et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia Hypertension 1999 34: 1281–1286

    Article  CAS  PubMed  Google Scholar 

  65. Staessen JA, Wang JG, Thijs L . Cardiovascular protection and blood pressure reduction: a meta-analysis Lancet 2001 358: 1305–1315

    Article  CAS  PubMed  Google Scholar 

  66. Staessen JA et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials Lancet 2000 355: 865–872

    Article  CAS  PubMed  Google Scholar 

  67. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344: 1383–1389

  68. Pfeffer MA et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. CARE investigators Am J Cardiol 1995 76: 98C–106C

    Article  CAS  PubMed  Google Scholar 

  69. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 1998 339: 1349–1357

  70. Shepherd J et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 1995 333: 1301–1307

    Article  CAS  PubMed  Google Scholar 

  71. Downs JR et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 1998 279: 1615–1622

    Article  CAS  PubMed  Google Scholar 

  72. Rubins HB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 1999 341: 410–418

    Article  CAS  PubMed  Google Scholar 

  73. Haim M et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry Circulation 1999 100: 475–482

    Article  CAS  PubMed  Google Scholar 

  74. Byington RP et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program Circulation 1995 92: 2419–2425

    Article  CAS  PubMed  Google Scholar 

  75. Sacks FM et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project Circulation 2000 102: 1893–1900

    Article  CAS  PubMed  Google Scholar 

  76. Sacks FM et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 1996 335: 1001–1009

    Article  CAS  PubMed  Google Scholar 

  77. Sposito AC et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril) Am J Cardiol 1999 83: 1497–1499 A8

    Article  CAS  PubMed  Google Scholar 

  78. Davis BR et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group Am J Hypertens 1996 9: 342–360

    Article  CAS  PubMed  Google Scholar 

  79. Grimm Jr RH et al. Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Hypertension 2001 37: 19–27

    Article  CAS  PubMed  Google Scholar 

  80. Sever PS et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators J Hypertens 2001 19: 1139–1147

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemical Pathology, Lipid Unit, St Thomas' Hospital, London, UK

    A S Wierzbicki

Authors
  1. A S Wierzbicki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wierzbicki, A. Lipid lowering: another method of reducing blood pressure?. J Hum Hypertens 16, 753–760 (2002). https://doi.org/10.1038/sj.jhh.1001483

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001483

Keywords

This article is cited by

Search

Advanced search

Quick links